The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.

Détails

ID Serval
serval:BIB_090D26633262
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.
Périodique
Annals of the rheumatic diseases
Auteur(s)
Lazarevic D., Pistorio A., Palmisani E., Miettunen P., Ravelli A., Pilkington C., Wulffraat N.M., Malattia C., Garay S.M., Hofer M., Quartier P., Dolezalova P., Penades I.C., Ferriani V.P., Ganser G., Kasapcopur O., Melo-Gomes J.A., Reed A.M., Wierzbowska M., Rider L.G., Martini A., Ruperto N.
Collaborateur(s)
Paediatric Rheumatology International Trials Organisation (PRINTO)
ISSN
1468-2060 (Electronic)
ISSN-L
0003-4967
Statut éditorial
Publié
Date de publication
05/2013
Peer-reviewed
Oui
Volume
72
Numéro
5
Pages
686-693
Langue
anglais
Notes
Publication types: Comparative Study ; Journal Article ; Research Support, N.I.H., Intramural ; Research Support, Non-U.S. Gov't ; Validation Study
Publication Status: ppublish
Résumé
To develop data-driven criteria for clinically inactive disease on and off therapy for juvenile dermatomyositis (JDM).
The Paediatric Rheumatology International Trials Organisation (PRINTO) database contains 275 patients with active JDM evaluated prospectively up to 24 months. Thirty-eight patients off therapy at 24 months were defined as clinically inactive and included in the reference group. These were compared with a random sample of 76 patients who had active disease at study baseline. Individual measures of muscle strength/endurance, muscle enzymes, physician's and parent's global disease activity/damage evaluations, inactive disease criteria derived from the literature and other ad hoc criteria were evaluated for sensitivity, specificity and Cohen's κ agreement.
The individual measures that best characterised inactive disease (sensitivity and specificity >0.8 and Cohen's κ >0.8) were manual muscle testing (MMT) ≥78, physician global assessment of muscle activity=0, physician global assessment of overall disease activity (PhyGloVAS) ≤0.2, Childhood Myositis Assessment Scale (CMAS) ≥48, Disease Activity Score ≤3 and Myositis Disease Activity Assessment Visual Analogue Scale ≤0.2. The best combination of variables to classify a patient as being in a state of inactive disease on or off therapy is at least three of four of the following criteria: creatine kinase ≤150, CMAS ≥48, MMT ≥78 and PhyGloVAS ≤0.2. After 24 months, 30/31 patients (96.8%) were inactive off therapy and 69/145 (47.6%) were inactive on therapy.
PRINTO established data-driven criteria with clearly evidence-based cut-off values to identify JDM patients with clinically inactive disease. These criteria can be used in clinical trials, in research and in clinical practice.
Mots-clé
Adrenal Cortex Hormones/therapeutic use, Child, Child, Preschool, Databases, Factual/standards, Databases, Factual/statistics & numerical data, Dermatomyositis/diagnosis, Dermatomyositis/drug therapy, Evidence-Based Medicine/standards, Evidence-Based Medicine/statistics & numerical data, Female, Follow-Up Studies, Humans, Immunosuppressive Agents/therapeutic use, Longitudinal Studies, Male, Prospective Studies, Randomized Controlled Trials as Topic, Reference Standards, Rheumatology/standards, Rheumatology/statistics & numerical data, Sensitivity and Specificity
Pubmed
Web of science
Création de la notice
03/05/2013 19:34
Dernière modification de la notice
03/05/2020 6:01
Données d'usage